INTRODUCTION
Patients with autoimmune rheumatic diseases are at increased risk of systemic and generalized infections, which result in increased morbidity and mortality rates in this patient group. Most commonly, infections affect the upper and lower respiratory tract as well as the urinary tract. Patients with autoimmune rheumatic diseases are also susceptible to infections of the skin, soft tissues, and central nervous system. 1 Infections in patients with autoimmune rheumatic diseases are related to immune defects associated with the disease (eg, impaired phagocytosis, defects of cellular immunity, and reduced Serum samples were used to assess the prevalence of antibodies against L. pneumophila. The serum was obtained from 5 ml of venous blood collected into tubes containing no anticoagulant (MEDLAB-PRODUCTS, Raszyn, Poland). The blood was centrifuged for 10 minutes at 1500 revolutions/minute. Then, 500 μl of the serum was collected into sterile plastic Eppendorf SafeLock tubes (Meranco, Poznań, Poland) and stored at -70°C until further testing.
Immunoglobulin (Ig) M and IgG anti-L. pneumophila serogroups for SG 1-7 were identified by an enzyme-linked immunosorbent assay (ELISA), using commercially available kits (EUROIMMUN, Lübeck, Germany): ELISA IgM SG 1-7 against L. pneumophila and ELISA IgG SG 1-7 against L. pneumophila. The diagnostic antigen in these kits is specific for L. pneumophila SG 1-7 lipopolysaccharide (SG 1, Philadelphia-1; SG 2, Togus-1; SG 3, Blommington-2; SG 4, Los Angeles-1; SG 5, Dallas 1E; SG 6, Chicago 2; SG 7, Chicago 8). IgG antibodies against L. pneumophila SG 1-7 were tested in all patients with autoimmune rheumatic diseases, while IgM antibodies were tested in all patients who were positive for IgG (SG 1-7).
In order to specify the factor inducing a humoral immune response in patients with positive antibody results for IgG class SG 1-7, antibodies for the most pathogenic serogroup (SG 1) L. pneumophila were marked using a commercially available ELISA kit, anti-L. pneumophila SG 1 ELI-SA IgG (VIRCELL MICROBIOLOGISTS , Granada, Spain). All tests were performed according to the manufacturers' instructions. The absorbance measurement of each well of the 96-well microplates was performed using Multiscan RC Labsystem (Helsinki, Finland). The test protocols were prepared using the Genesis program, version 3.03.
The potential risk factors for L. pneumophila infection were analyzed in patients with positive results. Patients were interviewed using a questionnaire. The risk factors were divided into 2 groups: individual and environmental. The first group included cigarette smoking, alcohol abuse, chronic obstructive pulmonary disease, diabetes, cancer, immunosuppressive therapy, and steroid therapy. The second group included a visit to the dentist, sanatorium treatment, travel, and the use of jacuzzi, water massage, inhalation, or air conditioning within the 2 months preceding the study.
Patients with autoimmune rheumatic diseases and the control group with positive results for antibodies against L. pneumophila had no history of Legionella spp. infection or infection of any other etiology in the 2 months preceding the study.
Data were presented as means ± standard deviations and analyzed using the χ 2 test. A P value of less than 0.05 was considered statistically significant. A statistical analysis was performed using STATISTICA version 9.0 (StatSoft, Inc., Kraków, Poland).
(Legionnaires disease, pneumonic form of legionellosis). The infection occurs through the inhalation of aerosol or consumption of water contaminated with Legionella pneumophila (L. pneumophila). 4, 5 Legionella is ubiquitous in water environments worldwide. The bacteria may colonize hot and cold water distribution systems, fountains, air-conditioning systems, cooling towers, nebulizers, and medical equipment containing water. 5 L. pneumophila species are responsible for the majority of diagnosed cases of Legionnaires disease (about 80%-90%), including from 60% to 90% of the most virulent L. pneumophila belonging to serogroup (SG) 1. The serogroups other than L. pneumophila SG 1 are involved in about 20% to 30% of infections (mainly SG 4 and 6). Only from 10% to 20% of the infections are caused by species other than L. pneumophila ("Legionella-like"). [4] [5] [6] From 2009 to 2014, 98 cases of legionellosis were reported in Poland.
7 It should be emphasized that legionellosis is detected in Poland relatively rarely, but according to some experts, the disease is much more prevalent. This is due to the lack of studies investigating the etiological factors of pneumonia.
The virulence and number of microorganisms penetrating into the lungs, as well as the immune status of an individual exposed to contact with the pathogen, play a major role in the development of the infection. 5, 8 So far, there have been no studies in Poland investigating the prevalence of Legionella antibodies in patients with autoimmune rheumatic diseases. Therefore, the aim of the study was to assess the prevalence of anti-L. pneumophila antibodies in patients with autoimmune rheumatic diseases. Moreover, we analyzed the generally accepted risk factors (individual and environmental) for the development of clinical infection in patients with positive antibody results. The bacteria of the genus Legionella are intracellular pathogens. A host immune response to these pathogens is significantly different than that directed against extracellular pathogens, and depends on the cell-type-specific response. A minor role is attributed to the humoral response because of the ability of Legionella to proliferate inside macrophages, which makes the bacteria resistant to the neutralizing effect of antibodies. Cytotoxic T lymphocytes and TNF-α, interferon γ, interleukin (IL) 1, IL-6, and IL-12 play the key role in cellular response. 6 The risk of Legionella infection in patients with autoimmune rheumatic diseases is also largely determined by environmental factors, which are difficult to avoid owing to the chronic character of the disease, and, what follows, frequent hospitalizations, use of nonpharmacological treatment (such as physical therapy), or stays in sanatoria.
PATIENTS AND METHODS
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Most of the literature data indicate that Legionella infections in immunocompromised patients are characterized by severe clinical course and high mortality rates of up to 30%.
8 Therefore, in all cases of severe pneumonia, especially those with the presence of risk factors, Legionella etiology must be considered when choosing an antibiotic therapy. Empirical treatment of pneumonia in patients with autoimmune rheumatic diseases should always include an antibiotic/chemotherapeutic agent with activity against Legionella spp. Currently, in the treatment of Legionella infections, the use of newer macrolides (azithromycin, clarithromycin), fluoroquinolones In all patients with positive antibody results, the potential individual and environmental risk factors for Legionella infection were found. Individual risk factors were as follows: immunosuppressive therapy in 5 patients, glucocorticosteroid therapy in 5, diabetes in 1, chronic obstructive pulmonary disease in 1, and cigarette smoking in 1. Environmental factors were as follows: a history of sanatorium treatment in 2 patients, a visit to the dentist in 1, and the use of inhalers in 1 (TABLE 2). In the control group, positive results were obtained in 9 cases (9%): IgM antibodies were detected in 6 (6%), and IgGin 3 (3%). The borderline results were obtained in 17 cases (17%): IgM in 4 (4%), and IgG-in 13 (13%). The antibodies against L. pneumophila SG 1 were not detected in the control group with positive antibody results for L. pneumophila SG 1-7. The results of the study and control groups are presented in TABLE 3. The prevalence of IgG antibodies against L. pneumophila SG 1-7 in patients with autoimmune rheumatic diseases was comparable to that in the control group (4.2% vs 3%; P = 0.45). Reference ranges for inflammatory markers are given in brackets.
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cells no history of influenza-like symptoms or pneumonia, indicating the presence of immune response to Legionella. The frequency of antibodies against L. pneumophila in our patients was comparable to that in healthy individuals, but the results might have been biased by the selection of the study population and methods. A number of studies have shown that the administration of glucocorticoids or immunomodulatory drugs increases the risk of infection in patients with autoimmune rheumatic diseases. It should be emphasized that the risk of infection increases with an increase in the dose and duration of treatment.
17,18 Moreover, the host's underlying disease state, which influences the dose and duration of treatment, largely determines variability in the risk of infection in clinical practice.
19
(ciprofloxacin), and rifampicin in combination therapy is required.
9
So far, there have been no studies investigating the exposure of patients with autoimmune rheumatic diseases to Legionella by measuring the levels of specific antibodies. According to the PubMed database, there have been reports of Legionella cases in patients with various rheumatic diseases who were treated with anti-TNF-α.
10-16
In our study, in patients with autoimmune rheumatic diseases, positive results of IgM or IgG anti-L. pneumophila SG 1-7 were obtained in 7 patients (4%). Two patients had both classes of antibodies (IgM and IgG). We did not observe specific antibodies for the most virulent anti-L. pneumophila SG 1 in any of the study participants. In patients with positive results, there was In our study, 5 of 7 patients positive for antibodies against L. pneumophila were treated with glucocorticoids. The fact that a single patient with antibodies had received glucocorticoids is not sufficient for risk calculation.
In contrast to the reports suggesting the association of anti-TNF-α therapy with Legionella, [10] [11] [12] [13] [14] [15] [16] patients with positive results in our study were not treated with anti-TNF-α. A study conducted by Tubach et al 11 showed that the relative risk of Legionnaires disease in patients receiving anti-TNF-α therapy was between 16.5 and 21 compared with the overall population.
In conclusion, the frequency of antibodies against L. pneumophila in our patients is comparable to that in healthy individuals, but the L. pneumophila should be recognized as a potential pathogen. A positive test result indicates that Legionella occur in the environment. This also confirms the existing infection hazard. Primary disease condition, immunosuppressive therapy, and other risk factors should not be ignored even if patients are asymptomatic. Although the incidence of Legionella infection is low, its early detection and treatment in patients at risk are clinically important because of high mortality rates.
